APLS

Biogen Taps Alloy Platform To Push Antisense Drug Pipeline Forward

04/07 08:54 am

Deal Dispatch: McCormick, Unilever Merge, Sysco Acquires Jetro Restaurant Depot For $29 Billion, QVC Considers Bankruptcy

04/03 10:35 am

Biogen Lands Two Fast-Growing Drugs In Blockbuster Apellis Deal

03/31 10:16 am

This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story

03/21 07:19 pm

Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference

02/23 08:00 am

TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600

01/27 07:02 pm

Silver Jumps To $89 After Soft CPI, JPMorgan Falls 3%: What's Moving Markets Tuesday?

01/13 02:04 pm

Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference

01/12 08:00 am

Geographic Atrophy Market to Surge Significantly During the Forecast Period (2025–2034) Due to Rising Adoption of Complement Inhibitor Therapies | DelveInsight

12/01 02:00 pm

Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference

11/05 08:00 am

Complement 3 Glomerulopathy Market Poised for Phenomenal Expansion at a CAGR of 37.2% During the Forecast Period (2025–2034) Owing to the Launch of Promising Therapies Targeting C3, C5, MASP-3, and RNAi | DelveInsight

10/22 01:00 pm

New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week

10/20 07:00 am

Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences

08/27 07:00 am

FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older

07/28 07:19 pm

Comprehensive Age-related Macular Degeneration Market Analysis: Trends and Developments Across All Types

06/16 01:00 pm

Why Apellis Pharmaceuticals Wilted on Wednesday

05/07 06:09 pm

Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

02/24 08:00 am

Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN

02/20 03:00 am

Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

02/14 08:00 am

Investigation Alert: MacroGenics, Apellis Pharmaceuticals, Teradata and Maplebear - Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information

02/06 03:40 pm

Apellis Receives Approval of SYFOVRE® (pegcetacoplan) in Australia for Geographic Atrophy (GA)

01/27 05:00 pm

Ophthalmic Drugs Global Market Report 2025: Innovations in Retinal Disorders, Glaucoma Drive Global Ophthalmic Medicines Surge

01/13 05:46 am

Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

01/06 08:00 am

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

11/27 08:00 am

Why Apellis Pharmaceuticals Stock Was Tumbling on Tuesday

11/05 05:47 pm

1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street Analyst

10/29 05:51 am

2023 Vision Health Report: Post Pandemic Recovery-Challenges Remain

10/28 10:56 am

Investigation Alert: MacroGenics, Apellis Pharmaceuticals, Teradata and Maplebear - Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information

10/23 05:39 pm

Geographic Atrophy (GA) Market Size to Hit USD 50.0 Billion by 2032 with a 8.6% CAGR – SNS Insider

09/20 09:53 am

Apellis (APLS) Falls on Second Negative CHMP Opinion for GA Drug

07/01 08:44 am

What Analysts Are Saying About Apellis Pharmaceuticals Stock

06/28 04:02 pm

Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU

06/28 06:57 am

Apellis (APLS) Up on Upbeat GA Data From Long-Term Syfovre Study

06/11 09:48 am

Why Is Apellis Pharmaceuticals (APLS) Down 1.9% Since Last Earnings Report?

06/06 11:31 am

Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference

06/05 07:00 am

Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 15 Analysts

05/28 10:00 am

Apellis (APLS) Posts Upbeat One-Year Kidney Diseases Study Data

05/27 12:33 pm

Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress

05/24 10:00 am

In-Depth Examination Of 14 Analyst Recommendations For Apellis Pharmaceuticals

05/08 02:00 pm

Apellis' (APLS) Q1 Earnings Match Estimates, Revenues Beat

05/07 11:19 am

Apellis Pharmaceuticals (APLS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

05/07 09:30 am

Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Tops Revenue Estimates

05/07 08:15 am

Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results

05/07 07:05 am

Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference

05/06 07:00 am

Analysts Estimate Syros Pharmaceuticals, Inc. (SYRS) to Report a Decline in Earnings: What to Look Out for

05/01 10:01 am

Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

05/01 07:00 am

Will Apellis Pharmaceuticals, Inc. (APLS) Report Negative Earnings Next Week? What You Should Know

04/30 10:00 am

Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)

04/26 07:15 am

Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results

04/23 07:00 am

Expert Ratings For Apellis Pharmaceuticals

04/15 10:00 am